| URL | https://bioprocessintl.com/bioprocess-insider/faci |
| Source | https://bioprocessintl.com |
| Date Published | 05/09/2022 |
| Author Name | Dan Stanton |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Parent company | Matica Biotechnology |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2022 |
| Domestically, the work will be done: | In-house |
| Country(ies) from which reshored: | Korea, Republic of |
| City reshored to: | College Station |
| State(s) reshored to: | TX |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | cell, gene therapy |
| What domestic positive factors made reshoring more attractive? | Skilled workforce availability/training |